| 1 |
Lim YL, Bohelay G, Hanakawa S, Musette P, Janela B. Autoimmune Pemphigus: Latest Advances and Emerging Therapies. Front Mol Biosci 2022;8:808536. [DOI: 10.3389/fmolb.2021.808536] [Reference Citation Analysis]
|
| 2 |
Helm TN, Helm MF, Helm KF. Consider drug induced pemphigus before establishing a diagnosis of paraneoplastic pemphigus (PNP). Int Immunopharmacol 2021;99:107967. [PMID: 34284289 DOI: 10.1016/j.intimp.2021.107967] [Reference Citation Analysis]
|
| 3 |
Stumpf N, Huang S, Hall LD, Hsu S. Differentiating Pemphigus Foliaceus From Pemphigus Vulgaris in Clinical Practice. Cureus 2021;13:e17889. [PMID: 34548989 DOI: 10.7759/cureus.17889] [Reference Citation Analysis]
|
| 4 |
Heydari P, Kharaziha M, Varshosaz J, Javanmard SH. Current knowledge of immunomodulation strategies for chronic skin wound repair. J Biomed Mater Res B Appl Biomater 2021. [PMID: 34318595 DOI: 10.1002/jbm.b.34921] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Nili A, Salehi Farid A, Asgari M, Tavakolpour S, Mahmoudi H, Daneshpazhooh M. Current status and prospects for the diagnosis of pemphigus vulgaris. Expert Rev Clin Immunol 2021;17:819-34. [PMID: 34162306 DOI: 10.1080/1744666X.2021.1945925] [Reference Citation Analysis]
|
| 6 |
Marinović B, Miše J, Jukić IL, Bukvić Mokos Z. Pemphigus-The Crux of Clinics, Research, and Treatment during the COVID-19 Pandemic. Biomedicines 2021;9:1555. [PMID: 34829784 DOI: 10.3390/biomedicines9111555] [Reference Citation Analysis]
|
| 7 |
Somerville E, Gebauer K, Mclean‐tooke A. Treatment of pemphigus in Australia: Aligning current practises with global recommendations. Aust J Dermatology. [DOI: 10.1111/ajd.13804] [Reference Citation Analysis]
|
| 8 |
Oya K, Fujii M, Taguchi S. Development of pemphigus vulgaris during treatment with dipeptidyl peptidase-4 inhibitors: a case report. Dermatol Ther 2021;34:e14982. [PMID: 33993628 DOI: 10.1111/dth.14982] [Reference Citation Analysis]
|
| 9 |
Tavakolpour S, Aryanian Z, Seirafianpour F, Dodangeh M, Etesami I, Daneshpazhooh M, Balighi K, Mahmoudi H, Goodarzi A. A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns. Immunopharmacol Immunotoxicol 2021;:1-12. [PMID: 34287098 DOI: 10.1080/08923973.2021.1953063] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
